EGFR is altered in 31.54% of glioblastoma patients with EGFR Amplification present in 33.16% of all glioblastoma patients [4].

EGFR Amplification is an inclusion criterion in 15 clinical trials for glioblastoma, of which 10 are open and 5 are closed. Of the trials that contain EGFR Amplification and glioblastoma as inclusion criteria, 6 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), 7 are phase 2 (4 open), and 1 is phase 2/phase 3 (1 open) [5].

EGFR is altered in 7.61% of malignant solid tumor patients with EGFR Amplification present in 2.89% of all malignant solid tumor patients [4].

EGFR Amplification is an inclusion criterion in 9 clinical trials for malignant solid tumor, of which 6 are open and 3 are closed. Of the trials that contain EGFR Amplification and malignant solid tumor as inclusion criteria, 6 are phase 1 (3 open) and 3 are phase 2 (3 open) [5].

EGFR is altered in 22.89% of non-small cell lung carcinoma patients with EGFR Amplification present in 5.19% of all non-small cell lung carcinoma patients [4].

EGFR Amplification is an inclusion criterion in 4 clinical trials for non-small cell lung carcinoma, of which 4 are open and 0 are closed. Of the trials that contain EGFR Amplification and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [5].

EGFR is altered in 5.88% of gastric carcinoma patients with EGFR Amplification present in 4.26% of all gastric carcinoma patients [4].

EGFR Amplification is an inclusion criterion in 3 clinical trials for gastric carcinoma, of which 2 are open and 1 is closed. Of the trials that contain EGFR Amplification and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [5].

EGFR is altered in 6.88% of squamous cell lung carcinoma patients with EGFR Amplification present in 3.87% of all squamous cell lung carcinoma patients [4].

EGFR Amplification is an inclusion criterion in 3 clinical trials for squamous cell lung carcinoma, of which 2 are open and 1 is closed. Of the trials that contain EGFR Amplification and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [5].

EGFR is altered in 2.76% of breast carcinoma patients with EGFR Amplification present in 1.33% of all breast carcinoma patients [4].

EGFR Amplification is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 2 are open and 1 is closed. Of the trials that contain EGFR Amplification and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [5].

EGFR is altered in 26.34% of malignant glioma patients with EGFR Amplification present in 27.24% of all malignant glioma patients [4].

EGFR Amplification is an inclusion criterion in 2 clinical trials for malignant glioma, of which 1 is open and 1 is closed. Of the trials that contain EGFR Amplification and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

EGFR is altered in 19.88% of glioma patients with EGFR Amplification present in 20.46% of all glioma patients [4].

EGFR Amplification is an inclusion criterion in 2 clinical trials for glioma, of which 1 is open and 1 is closed. Of the trials that contain EGFR Amplification and glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [5].

EGFR is altered in 16.31% of anaplastic astrocytoma patients with EGFR Amplification present in 12.36% of all anaplastic astrocytoma patients [4].

EGFR Amplification is an inclusion criterion in 2 clinical trials for anaplastic astrocytoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Amplification and anaplastic astrocytoma as inclusion criteria, 2 are phase 1 (2 open) [5].

EGFR is altered in 14.71% of gliosarcoma patients with EGFR Amplification present in 8.57% of all gliosarcoma patients [4].

EGFR Amplification is an inclusion criterion in 2 clinical trials for gliosarcoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Amplification and gliosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

EGFR is altered in 5.0% of adenocarcinoma of the gastroesophageal junction patients with EGFR Amplification present in 4.68% of all adenocarcinoma of the gastroesophageal junction patients [4].

EGFR Amplification is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 1 is closed. Of the trials that contain EGFR Amplification and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (1 open) [5].

EGFR is altered in 8.7% of diffuse astrocytoma patients with EGFR Amplification present in 3.12% of all diffuse astrocytoma patients [4].

EGFR Amplification is an inclusion criterion in 2 clinical trials for diffuse astrocytoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Amplification and diffuse astrocytoma as inclusion criteria, 2 are phase 2 (2 open) [5].

EGFR is altered in 3.22% of colorectal carcinoma patients with EGFR Amplification present in 1.3% of all colorectal carcinoma patients [4].

EGFR Amplification is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Amplification and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

EGFR is altered in 4.38% of urothelial carcinoma patients with EGFR Amplification present in 1.24% of all urothelial carcinoma patients [4].

EGFR Amplification is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain EGFR Amplification and urothelial carcinoma as inclusion criteria, 2 are phase 2 (1 open) [5].

EGFR is altered in 1.0% of pancreatic carcinoma patients with EGFR Amplification present in 0.16% of all pancreatic carcinoma patients [4].

EGFR Amplification is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Amplification and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

EGFR Amplification is an inclusion criterion in 2 clinical trials for chordoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Amplification and chordoma as inclusion criteria, 2 are phase 1 (2 open) [5].

EGFR is altered in 9.52% of hypopharyngeal squamous cell carcinoma patients with EGFR Amplification present in 14.29% of all hypopharyngeal squamous cell carcinoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for hypopharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR is altered in 12.94% of laryngeal squamous cell carcinoma patients with EGFR Amplification present in 12.31% of all laryngeal squamous cell carcinoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for laryngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR is altered in 12.94% of malignant laryngeal neoplasm patients with EGFR Amplification present in 12.31% of all malignant laryngeal neoplasm patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR is altered in 14.71% of glioblastoma, IDH-wildtype patients with EGFR Amplification present in 8.57% of all glioblastoma, IDH-wildtype patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for glioblastoma, IDH-wildtype, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and glioblastoma, IDH-wildtype as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR is altered in 8.25% of lip and oral cavity carcinoma patients with EGFR Amplification present in 8.13% of all lip and oral cavity carcinoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR is altered in 8.25% of oral cavity carcinoma patients with EGFR Amplification present in 8.13% of all oral cavity carcinoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR is altered in 8.25% of oral cavity squamous cell carcinoma patients with EGFR Amplification present in 8.13% of all oral cavity squamous cell carcinoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for oral cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR is altered in 8.33% of esophageal carcinoma patients with EGFR Amplification present in 7.64% of all esophageal carcinoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR is altered in 6.43% of head and neck squamous cell carcinoma patients with EGFR Amplification present in 6.18% of all head and neck squamous cell carcinoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

EGFR is altered in 26.09% of lung adenocarcinoma patients with EGFR Amplification present in 5.25% of all lung adenocarcinoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and lung adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR is altered in 6.25% of anaplastic oligoastrocytoma patients with EGFR Amplification present in 4.88% of all anaplastic oligoastrocytoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for anaplastic oligoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and anaplastic oligoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

EGFR is altered in 5.93% of gastric adenocarcinoma patients with EGFR Amplification present in 4.3% of all gastric adenocarcinoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains EGFR Amplification and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

EGFR is altered in 7.14% of nasal cavity and paranasal sinus carcinoma patients with EGFR Amplification present in 4.0% of all nasal cavity and paranasal sinus carcinoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR is altered in 7.18% of cancer patients with EGFR Amplification present in 2.69% of all cancer patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains EGFR Amplification and cancer as inclusion criteria, 1 is early phase 1 (0 open) [5].

EGFR is altered in 4.04% of oropharyngeal carcinoma patients with EGFR Amplification present in 2.54% of all oropharyngeal carcinoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR is altered in 4.04% of oropharyngeal squamous cell carcinoma patients with EGFR Amplification present in 2.54% of all oropharyngeal squamous cell carcinoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR is altered in 2.6% of hepatobiliary neoplasm patients with EGFR Amplification present in 1.23% of all hepatobiliary neoplasm patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR is altered in 2.5% of malignant hepatobiliary neoplasm patients with EGFR Amplification present in 1.23% of all malignant hepatobiliary neoplasm patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR is altered in 2.41% of cholangiocarcinoma patients with EGFR Amplification present in 1.21% of all cholangiocarcinoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR is altered in 1.84% of hepatocellular carcinoma patients with EGFR Amplification present in 0.9% of all hepatocellular carcinoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

EGFR is altered in 0.76% of meningioma patients with EGFR Amplification present in 0.61% of all meningioma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and meningioma as inclusion criteria, 1 is phase 1 (1 open) [5].

EGFR is altered in 2.82% of low grade glioma patients with EGFR Amplification present in 0.3% of all low grade glioma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

EGFR is altered in 1.63% of B-cell non-hodgkin lymphoma patients with EGFR Amplification present in 0.27% of all B-cell non-hodgkin lymphoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR is altered in 0.98% of malignant salivary gland neoplasm patients with EGFR Amplification present in 0.21% of all malignant salivary gland neoplasm patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR is altered in 1.02% of pancreatic adenocarcinoma patients with EGFR Amplification present in 0.16% of all pancreatic adenocarcinoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains EGFR Amplification and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

EGFR is altered in 1.36% of ovarian carcinoma patients with EGFR Amplification present in 0.1% of all ovarian carcinoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

EGFR Amplification is an inclusion criterion in 1 clinical trial for anal canal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and anal canal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

EGFR is altered in 3.89% of anaplastic oligodendroglioma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [5].

EGFR is altered in 0.74% of gastrointestinal stromal tumor patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR Amplification is an inclusion criterion in 1 clinical trial for malignant supratentorial neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and malignant supratentorial neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR is altered in 1.09% of medulloblastoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

EGFR is altered in 1.65% of multiple myeloma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR is altered in 1.37% of nasopharyngeal carcinoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EGFR Amplification is an inclusion criterion in 1 clinical trial for pituitary gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and pituitary gland carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

EGFR Amplification is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

EGFR is altered in 0.5% of uveal melanoma patients [4].

EGFR Amplification is an inclusion criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Amplification and uveal melanoma as inclusion criteria, 1 is phase 1 (1 open) [5].